as declared in These bacteria have become resistant to a large number of antibiotics, including carbapenems and third generation cephalosporins – the best available antibiotics for treating multi-drug resistant bacteria.
WHO publishes list of bacteria for which new antibiotics are urgently needed27 February 2017 | GENEVA – WHO today published its first ever list of antibiotic-resistant “priority pathogens” – a catalogue of 12 families of bacteria that pose the greatest threat to human health.
The list highlights in particular the threat of gram-negative bacteria that are resistant to multiple antibiotics.
The most critical group of all includes multidrug resistant bacteria that pose a particular threat in hospitals, nursing homes, and among patients whose care requires devices such as ventilators and blood catheters.
WHO’s first global priority pathogen list is an important new tool to secure and guide research and development related to new antibiotics.”
As it stated in The researchers developed potent analogs of a compound found in soil bacteria and showed that they could kill tuberculosis in the laboratory.
The new study concerns a compound called sansanmycin uridylpeptide, which is produced by soil bacteria and stops other bacteria growing around them.
Tuberculosis (TB) is a disease caused by the bacterium Mycobacterium tuberculosis.
They have produced synthetic versions of the natural compound and showed that they can kill the tuberculosis bacterium in the laboratory.
Researchers have discovered a compound found in soil bacteria that could lead to new drugs to combat tuberculosis, a global disease that is becoming increasingly resistant to current treatments.
As it stated in
Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics
Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibioticsThe World Health Organization was requested by Member States to develop a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development (R&D) of new and effective antibiotic treatments.
Previous PPLs, issued by the Centers for Disease Control and Prevention …
To date, the selection of pathogens for R&D activities has been largely guided by small and large pharmaceutical companies according to a variety of parameters, such as perceived/unmet medical need, pressure of investors, market size, scientific discovery potential, and availability of specific technologies.
This content may collect you by Sydney Connor